Key facts
- Rocket Heart’s last known valuation is $455.2M (Nov 2023).
- It has raised $13.8M; the latest was Later Stage VC in Aug 2025.
- Notable investors include China Aerospace Investment Holdings, Shenzhen Xingrun Asset Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Rocket Heart
- ·The full record, as it builds
Funding rounds
No funding rounds for Rocket Heart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rocket Heart
Manufacturer of implantable circulatory support systems intended for cardiac function restoration. The company offers miniaturized mechanical pumps, biocompatible vascular interfaces, telemetry-enabled monitoring units, and preoperative simulation tools with post-surgical training modules and clinical consultation services, serving specialized healthcare markets to deliver targeted heart failure interventions with improved patient outcomes, reduced procedural risks, and enhanced device adaptability across diverse physiological profiles.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2016
- Employees
- 13
- Website
- rocket-heart.com/
- Ownership
- Privately Held (backing)
Rocket Heart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rocket Heart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rocket Heart in its N-PORT filings yet. We sweep new filings monthly.